ZA89232B - Acylated uridine and cytidine and use thereof - Google Patents

Acylated uridine and cytidine and use thereof

Info

Publication number: ZA89232B
Authority: ZA; South Africa
Prior art keywords: cytidine; acylated; uridine; acylated uridine; administration
Prior art date: 1987-10-28

Application number

ZA89232A

Other languages

English (en)

Inventor

Reid Von Borstel

Von Borstel Reid

Michael Kevin Bamat

Kevin Bamat Michael

Original Assignee

Pro Neuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-28

Filing date

1989-01-11

Publication date

1990-06-27

1989-01-11 Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc

1990-06-27 Publication of ZA89232B publication Critical patent/ZA89232B/xx

Links

DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 5
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title abstract 4
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title abstract 2
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title abstract 2
206010019280 Heart failures Diseases 0.000 abstract 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
238000007429 general method Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
229940045145 uridine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)

ZA89232A 1987-10-28 1989-01-11 Acylated uridine and cytidine and use thereof ZA89232B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11592987A	1987-10-28	1987-10-28

Publications (1)

Publication Number	Publication Date
ZA89232B true ZA89232B (en)	1990-06-27

Family

ID=22364208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA89232A ZA89232B (en)	1987-10-28	1989-01-11	Acylated uridine and cytidine and use thereof

Country Status (12)

Country	Link
US (1)	US5583117A (fr)
EP (1)	EP0339075B1 (fr)
JP (6)	JP2894610B2 (fr)
AT (1)	ATE93236T1 (fr)
AU (1)	AU2789989A (fr)
CA (1)	CA1321994C (fr)
DE (1)	DE3883374T2 (fr)
HK (1)	HK1005740A1 (fr)
IL (1)	IL88208A (fr)
IN (1)	IN167680B (fr)
WO (1)	WO1989003837A1 (fr)
ZA (1)	ZA89232B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
US5968914A (en)	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7307166B1 (en)	1987-10-28	2007-12-11	Wellstat Therapeutics Corporation	Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US7776838B1 (en)	1987-10-28	2010-08-17	Wellstat Therapeutics Corporation	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5736531A (en)	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US7173017B1 (en)	1987-10-28	2007-02-06	Wellstat Therapeutics Corporation	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5470838A (en)	1987-10-28	1995-11-28	Pro-Neuron, Inc.	Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6329350B1 (en)	1987-10-28	2001-12-11	Pro-Neuron, Inc.	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
IT1219667B (it) *	1988-06-21	1990-05-24	Polifarma Spa	Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5216142A (en) *	1989-04-17	1993-06-01	Efamol Holdings Plc	Anti-virals
US4964959A (en) *	1990-04-12	1990-10-23	Olin Hunt Specialty Products Inc.	Process for preparing a nonconductive substrate for electroplating
IT1241984B (it) *	1990-06-13	1994-02-02	Polifarma Spa	Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
US5248672A (en) *	1990-11-01	1993-09-28	The Regents Of The University Of Michigan	Polysubstituted benzimidazole nucleosides as antiviral agents
CA2444071C (fr) *	1991-02-08	2008-10-07	Wellstat Therapeutics Corporation	Nucleosides oxypuriniques, leurs congeneres et leurs derives acyles sutlises dans la stimulation de l'hematopoiese
ATE205850T1 (de) *	1991-07-05	2001-10-15	Pro Neuron Inc	Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
ES2229212T3 (es) *	1992-12-08	2005-04-16	Wellstat Therapeutics Corporation	Precursores de nucleotidos de pirimidina para el tratamiento de la hepatitis inflamatoria.
DK0661051T3 (da) *	1993-10-11	2006-05-22	Viatris Gmbh	Medikament til behandling af hypertension
US5641758A (en) *	1993-11-10	1997-06-24	Kluge; Michael	Cytarabine derivatives, the preparation and use thereof
CN101066276A (zh) *	1994-07-01	2007-11-07	威尔斯塔特医疗公司	用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
US6703394B2 (en)	1996-02-16	2004-03-09	Medivir Ab	Acyclic nucleoside derivatives
US5869493A (en) *	1996-02-16	1999-02-09	Medivir Ab	Acyclic nucleoside derivatives
JP2001503767A (ja) *	1996-11-12	2001-03-21	メディヴィル・アクチボラグ	ヌクレオシド
DE69829784T2 (de) *	1997-08-15	2006-02-16	Medivir Ab	3'-Fluorierte Guanosinderivate zur Behandlung oder Prophylaxe von HBV- oder retroviralen Infektionen
US20070004670A1 (en) *	1998-07-31	2007-01-04	Richard Wurtman	Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) *	1999-07-30	2005-09-15	Wurtman Richard J.	Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8314064B2 (en) *	1998-07-31	2012-11-20	Massachusetts Institute Of Technology	Uridine administration stimulates membrane production
DK1870103T3 (da) *	1998-07-31	2010-01-11	Massachusetts Inst Technology	Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US8518882B2 (en) *	1998-07-31	2013-08-27	Massachusetts Institute Of Technology	Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8143234B2 (en)	1998-07-31	2012-03-27	Massachusetts Institute Of Technology	Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20060069061A1 (en) *	1998-07-31	2006-03-30	Dick Wurtman	Compositions containing uridine and choline, and methods utilizing same
US6136339A (en)	1998-08-21	2000-10-24	Gardiner; Paul T.	Food supplements and methods comprising lipoic acid and creatine
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) *	1998-08-31	2010-10-05	Wellstat Therapeutics Corporation	Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en)	1998-08-31	2011-03-29	Wellstat Therapeutics Corporation	Compositions and methods for treatment of mitochondrial diseases
BR0008447A (pt) *	1999-02-23	2002-01-15	Univ California	Métodos de tratamento de distúrbios mitocondriais
SE521031C2 (sv) *	1999-05-05	2003-09-23	Srinivas Uppugunduri	Nya specifika inhibitorer av akut och kronisk inflammation
WO2001068104A1 (fr)	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Composes servant a traiter des troubles psychiatriques ou des troubles provoques par la consommation abusive de substances psychoactives
RS20100077A (sr) *	2001-04-30	2010-10-31	Trommsdorff Gmbh. & Co. Kg. Arzneimittel	Farmaceutski aktivni estri uridina
CN1551778A (zh)	2001-09-05	2004-12-01	ɽ��ʽ��	用于糖尿病神经病变的药物组合物
AUPR951101A0 (en) *	2001-12-13	2002-01-24	Centre For Molecular Biology And Medicine	Method of treatment
PT1565055E (pt) *	2002-11-08	2013-09-16	Mclean Hospital Corp	Compostos para o tratamento da dependência e da privação de tabaco
KR101152470B1 (ko)	2003-08-13	2012-06-01	바이오콘 리미티드	치료제용 마이크로-입자 지방산 염 고형 투약 제형
KR20060092242A (ko) *	2003-11-03	2006-08-22	코그니스 아이피 매니지먼트 게엠베하	아실 리보뉴클레오시드 및 아실 데옥시리보뉴클레오시드
DK1706414T3 (da) *	2003-12-22	2008-10-13	Hoffmann La Roche	Fremgangsmåde til fluorcytidinderivater
EP1750509A4 (fr) *	2004-05-13	2010-03-24	Massachusetts Inst Technology	Effets de l'uridine sur la liberation de la dopamine
JP4656859B2 (ja) *	2004-05-19	2011-03-23	明治飼糧株式会社	酸化ストレス抑制剤
US7947661B2 (en)	2004-08-11	2011-05-24	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
US8658622B2 (en) *	2005-01-14	2014-02-25	Regents Of The University Of California	Methods and compositions for preventing and treating a disease related to glycan dysregulation
US20070114476A1 (en) *	2005-11-04	2007-05-24	Williams Christopher P	Low radiocarbon nucleotide and amino acid dietary supplements
EP2158462A4 (fr)	2007-05-03	2010-05-05	Radiocarb Genetics Inc	Compléments alimentaires à faible taux de carbone radioactif et procédés pour les fabriquer
BRPI0817387A2 (pt)	2007-11-02	2015-09-08	Massachusetts Inst Technology	métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
US8691775B2 (en)	2010-04-19	2014-04-08	Back Bay Scientific, Llc	Use of drugs that activate P2Y receptors to enhance synaptogenesis
WO2012125020A1 (fr) *	2011-03-14	2012-09-20	N.V. Nutricia	Méthode de traitement d'un traumatisme neurologique
JP5788715B2 (ja) *	2011-05-31	2015-10-07	キリンホールディングス株式会社	酸素消費量及びエネルギー消費量の低減剤
US9331955B2 (en)	2011-06-29	2016-05-03	Microsoft Technology Licensing, Llc	Transporting operations of arbitrary size over remote direct memory access
EP2556832B1 (fr) *	2011-08-12	2017-07-19	Universitätsklinikum Freiburg	Uridine et analogues d'uridine pour le traitement de la bronchopneumopathie chronique obstructive
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
DE202015105351U1 (de)	2015-10-09	2016-01-07	Apotheke am Schlossplatz Inh. Mario Ganster e.K.	Diätetische Zusammensetzung
SG11201811595SA (en) *	2016-06-27	2019-01-30	Ohio State Innovation Foundation	Liponucleotide-based therapy for ards
CN114469981A (zh) *	2021-12-16	2022-05-13	中国科学院动物研究所	尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3847898A (en) *	1969-05-27	1974-11-12	Upjohn Co	N4-trihaloethoxy carbonyl arabino-furanosyl cytosine 5'-esters
US3585188A (en) *	1969-06-16	1971-06-15	Takeda Chemical Industries Ltd	Process for producing 2'-deoxyuridine
GB1297398A (fr) *	1969-08-06	1972-11-22
US3894000A (en) *	1971-01-27	1975-07-08	Upjohn Co	Ara-cytidine derivatives and process of preparation
US3868451A (en) *	1971-03-30	1975-02-25	Abbott Lab	Adenosine-5{40 -esters in treating angina pectoris
US3975367A (en) *	1971-06-08	1976-08-17	The Upjohn Company	Arabinofuranosyl N4 -aminoacyl cytosine containing compounds
DE2147094A1 (de) *	1971-09-21	1973-04-05	Robugen Gmbh	Virostatisch wirksames arzneimittel
US4022963A (en) *	1972-06-08	1977-05-10	Deutsch Daniel Harold	Acetylation process for nucleoside compounds
US3991045A (en) *	1973-05-30	1976-11-09	Asahi Kasei Kogyo Kabushiki Kaisha	N4 -acylarabinonucleosides
JPS5119779A (en) *	1974-08-12	1976-02-17	Asahi Chemical Ind	N44 ashiru shichijinno seizoho
JPS5223085A (en) *	1975-08-12	1977-02-21	Ajinomoto Co Inc	Selective n-deacylation of n4- - acylcytidine derivatives
JPS5524150A (en) *	1978-08-09	1980-02-21	Taiho Yakuhin Kogyo Kk	Anti-malignant-tumor agent
JPS5635196A (en) *	1979-08-29	1981-04-07	Sanyo Electric Co	Sound identification system
JPS5791994A (en) *	1980-11-26	1982-06-08	Fuji Kagaku Kogyo Kk	5'-o-(n-alkylcarbamoylalanyl)-5-fluorouridine and its preparation
DE3100478A1 (de) *	1981-01-09	1982-08-12	Dr. Thilo & Co GmbH, 8021 Sauerlach	5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
JPS5849315A (ja) *	1981-09-18	1983-03-23	Mitsui Pharmaceut Inc	抗腫瘍剤
JPS60174797A (ja) *	1984-02-21	1985-09-09	Funai Corp	Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
FR2571201B1 (fr) *	1984-10-02	1987-01-02	Valeo	Procede de chauffage dans la masse d'une substance par exemple en vue d'une vulcanisation ou d'une polymerisation
IT1178044B (it) *	1984-10-09	1987-09-03	Polifarma Spa	Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
WO1987000435A1 (fr) *	1985-07-22	1987-01-29	Teijin Limited	Medicament antiviral
US4762823A (en) *	1985-10-16	1988-08-09	Sloan-Kettering Institute For Cancer Research	Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
FR2594022B1 (fr) *	1986-02-07	1988-05-27	Cousin Cie Ets A & M Freres	Articulation pour dossier de siege a grain composite.
JPH05223085A (ja) *	1992-02-07	1993-08-31	Daikin Ind Ltd	密閉形圧縮機

1988
- 1988-10-27 EP EP88909932A patent/EP0339075B1/fr not_active Expired - Lifetime
- 1988-10-27 HK HK98104859A patent/HK1005740A1/en not_active IP Right Cessation
- 1988-10-27 AU AU27899/89A patent/AU2789989A/en not_active Abandoned
- 1988-10-27 JP JP63509176A patent/JP2894610B2/ja not_active Expired - Lifetime
- 1988-10-27 DE DE88909932T patent/DE3883374T2/de not_active Expired - Lifetime
- 1988-10-27 CA CA000581429A patent/CA1321994C/fr not_active Expired - Lifetime
- 1988-10-27 AT AT88909932T patent/ATE93236T1/de not_active IP Right Cessation
- 1988-10-27 WO PCT/US1988/003823 patent/WO1989003837A1/fr not_active Ceased
- 1988-10-28 IL IL8820888A patent/IL88208A/en not_active IP Right Cessation
- 1988-10-28 IN IN755/MAS/88A patent/IN167680B/en unknown
1989
- 1989-01-11 ZA ZA89232A patent/ZA89232B/xx unknown
1993
- 1993-10-25 US US08/140,475 patent/US5583117A/en not_active Expired - Lifetime
1994
- 1994-12-07 JP JP6303877A patent/JPH07228535A/ja active Pending
1997
- 1997-02-20 JP JP03673497A patent/JP3474073B2/ja not_active Expired - Lifetime
2000
- 2000-12-13 JP JP2000379524A patent/JP2001192335A/ja not_active Withdrawn
2005
- 2005-12-28 JP JP2005380457A patent/JP2006137772A/ja not_active Withdrawn
2007
- 2007-09-07 JP JP2007233452A patent/JP2008019268A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0339075A1 (fr)	1989-11-02
IL88208A (en)	1996-10-16
JP2006137772A (ja)	2006-06-01
WO1989003837A1 (fr)	1989-05-05
JP2894610B2 (ja)	1999-05-24
CA1321994C (fr)	1993-09-07
JPH07228535A (ja)	1995-08-29
EP0339075B1 (fr)	1993-08-18
EP0339075A4 (fr)	1990-04-10
AU2789989A (en)	1989-05-23
JPH101436A (ja)	1998-01-06
JP2008019268A (ja)	2008-01-31
DE3883374D1 (de)	1993-09-23
JP3474073B2 (ja)	2003-12-08
IL88208A0 (en)	1989-06-30
JP2001192335A (ja)	2001-07-17
DE3883374T2 (de)	1993-12-09
US5583117A (en)	1996-12-10
HK1005740A1 (en)	1999-01-22
JPH02500372A (ja)	1990-02-08
IN167680B (fr)	1990-12-08
ATE93236T1 (de)	1993-09-15

Publication	Publication Date	Title
IL88208A0 (en)	1989-06-30	Acylated uridine and cytidine and uses thereof
EP0151989A3 (en)	1986-10-08	Means for the treatment of cardiac diseases
HU9008407D0 (en)	1991-07-29	Process for the production of purine nucleoside derivatives and medical preparations containing them as active agents
ES8606289A1 (es)	1986-04-16	Un procedimiento para la preparacion de piridazinaminas.
IL87885A (en)	1993-06-10	Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
UA34419C2 (uk)	2001-03-15	Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
AU3065989A (en)	1989-08-25	Polypeptide compounds having growth hormone releasing activity
FR2629715B1 (fr)	1993-09-03	Derives de l'adenosine, leur procede de preparation et leur utilisation en therapeutique
ES8801303A1 (es)	1987-12-16	Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
IT8547834A0 (it)	1985-03-20	Procedimento di trattamento di cellule con proteine ossee solubili per renderle idonee a stimolare la crescita di tessuti cartilaginei ed ossei,e prodotto ottenuto
ATE80790T1 (de)	1992-10-15	Zusammensetzung zur behandlung der haut.
IT1214738B (it)	1990-01-18	Perfezionamento negli impianti di stimolazione cardiaca mediante pacemaker
HU913776D0 (en)	1992-02-28	Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents
IE800102L (en)	1980-07-19	N-benzylimidazoles
GR3002377T3 (en)	1992-12-30	Ifosfamide-mesna-lyophilized composition and process to prepare it
EP0276536A3 (en)	1989-08-30	Use of buspirone for the improvement of short term memory
ES2002083A6 (es)	1988-07-01	Un metodo para preparar derivados de piroglutamida
AU2062288A (en)	1989-02-16	Combination of pyrimidine derivatives and retinoids, as separate components, for inducing and stimulating hair growth and reducing its loss
HUT46837A (en)	1988-12-28	Compositions of insectifuge and acarifuge activity containing alpha, omega-amino-alkohol derivatives as active components and process for producing the active components
IT218609Z2 (it)	1992-06-23	Supporto gonfiabile del busto e di altre parti del corpo umano.
GR3005481T3 (fr)	1993-05-24
DE69329802D1 (de)	2001-02-01	Syndecan-stimulierung der zellulären differenzierung
ES2000594A6 (es)	1988-03-01	Un procedimiento para la preparacion de tiazolonas
NO165542C (no)	1991-02-27	Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner.
EP0311322A3 (en)	1990-11-22	Pyridine or pyridazine derivatives as cardio-protective agents and for the treatment of ischemic disease, and process for their preparation